tetano
Editor, Senior Moderator
Sci Adv
. 2021 Jun 25;7(26):eabg4901.
doi: 10.1126/sciadv.abg4901. Print 2021 Jun.
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
Jacob T Heggestad[SUP] 1 [/SUP], David S Kinnamon[SUP] 1 [/SUP], Lyra B Olson[SUP] 2 [/SUP], Jason Liu[SUP] 1 [/SUP], Garrett Kelly[SUP] 1 [/SUP], Simone A Wall[SUP] 1 [/SUP], Solomon Oshabaheebwa[SUP] 1 [/SUP], Zachary Quinn[SUP] 1 [/SUP], Cassio M Fontes[SUP] 1 [/SUP], Daniel Y Joh[SUP] 1 3 [/SUP], Angus M Hucknall[SUP] 1 [/SUP], Carl Pieper[SUP] 4 [/SUP], Jack G Anderson[SUP] 5 [/SUP], Ibtehaj A Naqvi[SUP] 6 [/SUP], Lingye Chen[SUP] 7 [/SUP], Loretta G Que[SUP] 7 [/SUP], Thomas Oguin 3rd[SUP] 8 [/SUP], Smita K Nair[SUP] 6 9 [/SUP], Bruce A Sullenger[SUP] 1 6 10 [/SUP], Christopher W Woods[SUP] 5 8 [/SUP], Thomas W Burke[SUP] 5 [/SUP], Gregory D Sempowski[SUP] 8 [/SUP], Bryan D Kraft[SUP] 7 [/SUP], Ashutosh Chilkoti[SUP] 11 [/SUP]
Affiliations
Abstract
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.
. 2021 Jun 25;7(26):eabg4901.
doi: 10.1126/sciadv.abg4901. Print 2021 Jun.
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
Jacob T Heggestad[SUP] 1 [/SUP], David S Kinnamon[SUP] 1 [/SUP], Lyra B Olson[SUP] 2 [/SUP], Jason Liu[SUP] 1 [/SUP], Garrett Kelly[SUP] 1 [/SUP], Simone A Wall[SUP] 1 [/SUP], Solomon Oshabaheebwa[SUP] 1 [/SUP], Zachary Quinn[SUP] 1 [/SUP], Cassio M Fontes[SUP] 1 [/SUP], Daniel Y Joh[SUP] 1 3 [/SUP], Angus M Hucknall[SUP] 1 [/SUP], Carl Pieper[SUP] 4 [/SUP], Jack G Anderson[SUP] 5 [/SUP], Ibtehaj A Naqvi[SUP] 6 [/SUP], Lingye Chen[SUP] 7 [/SUP], Loretta G Que[SUP] 7 [/SUP], Thomas Oguin 3rd[SUP] 8 [/SUP], Smita K Nair[SUP] 6 9 [/SUP], Bruce A Sullenger[SUP] 1 6 10 [/SUP], Christopher W Woods[SUP] 5 8 [/SUP], Thomas W Burke[SUP] 5 [/SUP], Gregory D Sempowski[SUP] 8 [/SUP], Bryan D Kraft[SUP] 7 [/SUP], Ashutosh Chilkoti[SUP] 11 [/SUP]
Affiliations
- PMID: 34172447
- DOI: 10.1126/sciadv.abg4901
Abstract
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.